Suven gets patent for Alzheimer's compound
This article was originally published in Scrip
Executive Summary
The Indian biopharmaceutical company Suven Life Sciences has been granted patents on its clinical candidate (SUVN-502) for Alzheimer's disease in several countries. These include India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe and the patent is valid till June 2023, the company informed the Bombay Stock Exchange. SUVN-502 is a potent, highly selective, brain penetrant and orally active antagonist at a non-peripheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition such as attention deficient hyperactivity, Parkinson's disease and schizophrenia. The compound has completed Phase I single-ascending and multiple-ascending studies in Switzerland and has demonstrated safety at all doses, with potential as a once-daily treatment. Phase II proof-of-concept studies are expected next year. Suven has also claimed that some companies have initiated the process of due diligence for potential partnerships for SUVN-502.